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Abstract
Acute myocardial infarction causes lethal injury to cardiomyocytes during both is-
chaemia and reperfusion (IR). It is important to define the precise mechanisms by 
which they die in order to develop strategies to protect the heart from IR injury. 
Necrosis is known to play a major role in myocardial IR injury. There is also evidence 
for significant myocardial death by other pathways such as apoptosis, although this 
has been challenged. Mitochondria play a central role in both of these pathways of 
cell death, as either a causal mechanism is the case of mitochondrial permeability 
transition leading to necrosis, or as part of the signalling pathway in mitochondrial 
cytochrome c release and apoptosis. Autophagy may impact this process by removing 
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1  | INTRODUC TION
Ischaemic heart disease remains a major cause of morbidity and mor-
tality throughout the world, and is responsible for ~20% of deaths in 
the European Union in both men and women.1 Many of these deaths 
occur during an acute ischaemic event such as an ST-elevation 
myocardial infarction (STEMI). Although fatality rates immediately 
following acute myocardial infarction have decreased in most coun-
tries,1 infarct size remains a major determinant of outcome and is 
strongly associated with all-cause mortality and hospitalization for 
heart failure within the following year.2 Cardiomyocytes begin to die 
during exposure to prolonged ischaemia, and while reperfusion is 
necessary to limit this process, it causes a spike of further cell death 
that contributes to final infarct size.3 Thus, finding ways to limit car-
diomyocyte death during ischaemia and reperfusion (IR) has been 
the focus of extensive studies over the past 30 years.3 Myocardial 
IR is a complex process during which the ability of physiological pro-
cesses to return the cardiac cells to homeostasis is overwhelmed. A 
major cause of this is calcium overload which damages cellular com-
ponents and drains energy (ATP) as ion pumps in the sarcolemma 
and sarcoplasmic reticulum (SR) are engaged to return cytosolic cal-
cium back to appropriate levels.4,5 Mitochondrial calcium overload 
causes mitochondrial damage and further depletes ATP as it is uti-
lized to maintain mitochondrial membrane potential. In combination 
with oxidative stress and calcium overload, ATP levels may decrease 
to a critical level at which the ability of the cardiac cell to remain 
viable becomes compromised, and the cell undergoes uncontrolled 
death through a process of oncosis and necrosis, which is described 
in detail below. However, even before this step, programmed cell 
death pathways may be activated including apoptosis, necroptosis or 
pyroptosis. Although ultimately each of these pathways still results 
in the death of the cell, they can have profoundly different effects on 
the heart, for example in terms of the activation of an inflammatory 
response. Furthermore, as many of the pathways appear to overlap 
or utilize common cellular signalling components, modulation of one 
pathway may simply result in the cardiomyocyte dying by an alter-
native pathway. This review aims to provide insight into the differ-
ent types of cell death which myocardial cells may undergo during 
IR, with special emphasis on the role of mitochondria in those pro-
cesses, in order to understand how these processes can be targeted 
to protect the heart.6
It is important to note that the initial description and definition of 
several of the cell death pathways (apoptosis, pyroptosis, etc) were 
based on experimental observations in leucocytes, and they may 
have different manifestations in cardiomyocytes or other non-in-
flammatory cell types in the heart. In this review, we focus on cell 
death pathways occurring in cardiomyocytes. Clearly, mitochondria 
are central to the function of cardiomyocytes, occupying nearly 40% 
of the cytosolic volume,7 and providing the bulk of the ATP neces-
sary for contraction as well as ion pumps and metabolic processes 
essential for survival. It is therefore not surprising that mitochon-
dria appear to have a central place in the process of cardiomyocyte 
death.
2  | ONCOSIS AND NECROSIS
During myocardial ischaemia, oxygen is rapidly depleted, causing 
mitochondrial respiration to cease. Anaerobic metabolism is ac-
tivated within seconds of flow cessation, but is unable to provide 
sufficient ATP for maintaining sarcolemmal ion gradients and mito-
chondrial membrane potential (ΔΨm). ATP is further depleted by the 
F0F1ATPase running in reverse, expending ATP in a futile attempt to 
maintain ΔΨm. Eventually, the sarcolemmal ion pumps fail and the 
cell swells in a process called ‘oncosis’, which is defined as a pre-
lethal stage following cellular injury.8 Shortly afterwards, oncosis 
leads inevitably to necrosis, defined by the physical, chaotic disrup-
tion of the cell membrane. Many techniques for identification of 
dead (necrotic) cells rely on this permeability of the cell membrane, 
which allows dyes such as propodium iodide or trypan blue to enter 
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dysfunctional proteins or even entire mitochondria through a process called mi-
tophagy. More recently, roles for other programmed mechanisms of cell death such 
as necroptosis and pyroptosis have been described, and inhibitors of these pathways 
have been shown to be cardioprotective. In this review, we discuss both mitochon-
drial and mitochondrial-independent pathways of the major modes of cell death, their 
role in IR injury and their potential to be targeted as part of a cardioprotective strat-
egy. This article is part of a special Issue entitled ‘Mitochondria as targets of acute 
cardioprotection’ and emerged as part of the discussions of the European Union 
(EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, 
CA16225.
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necrosis, pyroptosis, reperfusion
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and stain the cell (Figure 1). However, it is important to note that 
membrane permeabilization, and hence necrosis, can occur second-
arily to cell death by any mechanism, including the later phase of 
apoptosis. Likewise, it should also be noted that various cell death 
modalities with the features of ruptured plasma membrane can 
occur in parallel. These facts can make it difficult to ascertain the 
F I G U R E  1   The major pathways of cell death that contribute to myocardial ischaemia and reperfusion injury. During initial oncosis, cells 
swell—this is reversible but can proceed to necrosis. Non-cardiomyocytes can die via a processes of apoptosis or necrosis/necroptosis, in 
addition to other types of cell death described herein. Cardiomyocytes die primarily via a process of necrosis/necroptosis in addition to 
other cell-death processes such as pyroptosis, but there is a little evidence for any contribution of apoptosis. Plasma membrane rupture is 
the terminal event, and this is mediated either by MLKL channels during necroptosis or by GSDMD pores during pyroptosis. Multiple cell-
death pathways can eventuate in plasma membrane permeabilization, as detected by dyes such as propodium iodide (resulting in red nuclei 
as shown) or trypan blue
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F I G U R E  2   Possible mitochondrial pathways of necroptosis. Ischaemia and reperfusion causes an increase in levels or phosphorylation 
and activation of RIP1 and RIP3 (receptor-interacting serine/threonine-protein kinase 1 and 3), MLKL (mixed-lineage kinase domain-like 
pseudokinase) and PGAM5 (phosphoglycerate mutase family member 5). RIP3 translocates to the mitochondria and interacts with PGAM5 
and DRP1. PGAM5 dephosphorylates and activates DRP1 leading to mitochondrial fission and dysfunction. Additionally, RIP3-mediated 
activation of CaMKII (Ca2+-calmodulin-dependent protein kinase) may trigger necroptosis via the MPTP. Mitochondrial dysfunction leads 
ultimately the formation of the necroptosome consisting of activated RIP1, RIP3 and MLKL, and necroptotic cell death ensues.
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precise cause of myocardial cell death, particularly when examining 
a single time-point.
Mitochondria play a critical role in the process of myocardial IR 
injury. In particular, upon reperfusion, when the supply of oxygen 
to the cardiac cells is re-introduced and mitochondrial respiration 
recommences. The mitochondrial substrate succinate, having accu-
mulated during ischaemia, provides a powerful source of electrons 
which produce oxygen radicals by reverse electron transport via 
complex I, resulting in oxidative stress (excess reactive oxygen spe-
cies or ROS).9 The rapid replenishment of oxygen and ATP to the 
cells is a double-edged sword. ATP is necessary to restore ionic ho-
meostasis but it also reactivates the sarcoplasmic reticulum ATPASE 
2A (SERCA2A) allowing it to pump Ca2+ back into the SR. However, 
hyperactivation of the SR Ca2+ release channel, RyR2, results in 
rapid cycles of SR Ca2+ uptake and spontaneous SR Ca2+ release. 
The restoration of ATP levels while cytosolic Ca2+ overload is still 
current also leads to hypercontraction of cardiomyocytes, which 
can be detected during the first few minutes of reperfusion by the 
appearance of ‘contraction band necrosis’ in haematoxylin and eo-
sin-stained myocardial histological sections.10 The excessive SR Ca2+ 
release contributes to mitochondrial Ca2+ uptake via the mitochon-
drial calcium uniporter (MCU), leading to mitochondrial Ca2+ over-
load and opening of the mitochondrial permeability transition pore 
(MPTP).11 With the MPTP open, the mitochondria are no longer able 
to maintain ΔΨm, and shortly afterwards, ATP stores are depleted, 
ion pumps cease functioning, and the cells die through a process of 
oncosis and necrosis.
It may be possible to target necrosis during the early stages of 
infarction in order to protect the heart from IR injury. Mice lack-
ing either the MPTP or the MCU have smaller infarct sizes follow-
ing IR.12-14 Cardioprotection against IR injury can also be achieved 
experimentally by activation of the MAPK/ERK1/2 or PI3K/AKT 
signalling pathways.15,16 Activation of the reperfusion injury salvage 
kinase (RISK) pathway protects the heart by delaying opening of the 
MPTP.17 At least in the isolated, perfused heart, blocking hypercon-
traction by lowering pH or administering inhibitors of the contractile 
machinery reduces infarct size, as does blocking of reverse electron 
flow by providing malonate.18-20 However, as will be discussed later, 
it cannot be ruled out that such previously reported MPTP opening 
associated with necrosis17 can be also a mechanism of other necro-
sis-like cell death modes, which have been identified more recently.13
3  | APOPTOSIS
Apoptosis is a form of cell death that can be distinguished micro-
scopically from oncosis by cell shrinkage, chromatin condensa-
tion and distinctive blebbing (budding) of the plasma membrane. 
Apoptosis can occur via intrinsic or extrinsic mechanisms but both 
result in mitochondrial outer membrane permeabilization (MOMP), 
Mode of 
cell death Key characteristics
Characteristics known to occur in 
cardiomyocytes
Necrosis Plasma membrane permeability; MPTP 
opening13
MPTP opening13; Plasma 
membrane permeability; 
Hypercontraction/contraction 
band necrosis10
Apoptosis Mitochondrial outer membrane 
permeabilization (MOMP), 
Mitochondrial cytochrome c release, 
caspase activation, DNA fragmentation 
cell shrinkage, Chromatin condensation, 
Plasma membrane blebbing21
Controversial; Mitochondrial 
fission41
Autophagy LC3-II; Pink1/Parkin accumulation at 
mitochondria44; BNIP3 up-regulation49; 
FUNDC1-ser13 dephosphorylation51
Similar to the process in other cell 
types58,59
Necroptosis Recruitment of cytosolic adaptor proteins 
to complex I62; Plasma membrane 
permeability; relocalization of pMLKL to 
the plasma membrane62; RIP3 activation
Similar to the process in other 
cell types 62; RIP3-mediated 
activation of CaMKII71
Pyroptosis NLRP3 inflammasome formation; 
Cleavage of GSDMD, caspase-1, 
pro-IL-18 and pro-IL-1β82-84
Believed to be similar to the 
process in other cell types87,91
Parthanatos Activation of poly(ADP-ribose) 
polymerase-1 (PARP-1)117
Believed to be similar to the 
process in other cell types
Ferroptosis Bid translocation to the mitochondria121; 
Loss of glutathione peroxidase 4122
Believed to be similar to the 
process in other cell types
Note: As some processes can overlap, not all features are necessarily diagnostic of the type of 
cell death and may depend on the time-point being examined (eg: most forms of cell death will 
ultimately result in plasma membrane permeability).
TA B L E  1   The key characteristics of 
the main cell death processes discussed 
in this review, and their manifestation in 
cardiomyocytes (if known)
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mitochondrial cytochrome c release, caspase activation, DNA frag-
mentation and cell blebbing.21
Early studies detected evidence of apoptosis along with necrotic 
cell death following myocardial IR.22 However, the relative contri-
bution of apoptosis to the extent of cardiac damage is still debated 
due to the large differences in its magnitude as reported by different 
investigators. DNA laddering, one of the hallmarks of apoptosis, was 
not detected in myocardium subjected to ischaemia alone, but was 
only observed after reperfusion, suggesting that the apoptotic com-
ponent of cell death in the myocardium is triggered at the time of 
reperfusion and does not manifest during the ischaemic period.23,24 
In contrast, other studies have shown that apoptosis begins either 
after prolonged myocardial ischaemia without reperfusion or after 
a brief period of ischaemia followed by reperfusion.25,26 Detection 
of pro-apoptotic factors and caspase activation during ischaemia in 
the absence of DNA fragmentation followed by a more massive in-
crease during reperfusion indicates that the apoptotic cascade is ini-
tiated during ischaemia, but is fully executed during reperfusion.27,28 
More supportive evidence for the acceleration of apoptosis during 
reperfusion comes from studies showing a reduction in infarct size 
using inhibitors of pro-apoptotic mediators at early reperfusion.29,30 
Studies in humans have also demonstrated the detection of apop-
totic cardiomyocytes in the border zone of the infarcted myocar-
dium within hours to days of infarction.31
In contrast to the above, other studies have argued against the 
significant role of apoptosis in IR-induced cell death, based on the 
fact that there is minimal expression of most proteins required for 
the apoptotic program in adult cardiomyocytes.32,33 In addition, 
using cardiac-specific knockout mice, it was conclusively shown that 
the executioner caspase-3 and caspase-7 do not significantly con-
tribute to the acute effects of myocardial IR injury.34 Even forced 
overexpression of caspase in cardiomyocytes is not able to trigger 
a full apoptotic response in cardiomyocytes during IR, although it 
does result in increased infarct sizes.35 This raises the possibility 
that the previous observations of apoptosis in the heart are likely to 
have been due to apoptosis of non-cardiomyocytes.21,32 Notably, as 
non-cardiomyocytes significantly outnumber cardiomyocytes in the 
heart, their apoptosis could easily account for the observed DNA 
laddering. Similarly, TUNEL staining is weak evidence for cardio-
myocyte apoptosis because ultrastructural studies have shown that 
TUNEL staining is present only in cardiomyocytes that have already 
died by necrosis.36 Of note, apoptosis of endothelial cells and leuco-
cytes would also be expected to indirectly affect cardiomyocyte cell 
survival and cardiac performance.32 Thus, anti-apoptotic strategies 
may still be cardioprotective.21 For example, a recently developed 
peptide targeting the FAS-dependent apoptotic signal during IR in-
jury decreased infarct size in mice, even when administration was 
delayed 30 minutes into reperfusion.37
Mitochondria play an important role in the execution of apop-
tosis. These organelles are the major contributors of ROS and the 
major target for ROS-induced damage. The mitochondrial apoptosis 
pathway is triggered by mitochondrial swelling and outer mitochon-
drial membrane rupture, thus favouring the release of pro-apoptotic 
factors such as cytochrome c and SMAC/Diablo from the intermem-
brane space into the cytosol.38 Oxidative stress and Ca2+ overload 
leading to MPTP opening may contribute to apoptosis by increasing 
MOMP and cytochrome c release.
Another important mechanism for mitochondrial quality control 
is mitochondrial fusion and fission. Mitochondrial fission is consid-
ered to be the prerequisite for the occurrence of mitophagy and sev-
eral studies revealed the causal relationship between mitochondrial 
fission and the induction of apoptosis.39,40 In this respect, it has been 
demonstrated that increased mitochondrial fission in the ischaemic 
heart contributes to apoptosis induction and infarct generation, 
while inhibiting mitochondrial fission reduces myocardial injury and 
improves cardiac function following myocardial infarction.41
4  | AUTOPHAGY
Mitochondrial damage negatively affects cardiomyocyte function 
via disruption of oxidative phosphorylation, Ca2+ dyshomeostasis, 
increased oxidative stress and incomplete digestion of mitochondrial 
DNA. These events play a role in triggering the formation of inflam-
masomes within cells.42 Thus, a process that contributes to the elim-
ination of toxic mitochondrial contents and mitochondrial quality 
control is crucial to the maintenance overall cardiomyocyte health. 
Mechanisms of mitochondrial degradation include mitochondrial au-
tophagy, also known as mitophagy, and micromitophagy, whereby 
lysosomes directly fuse with and degrade mitochondria.43 A well-
established mechanism of mitophagy in cardiomyocytes requires 
the accumulation of mitochondrial PTEN-induced putative kinase-1 
(PINK1) at depolarized mitochondrial outer membranes, which pro-
motes translocation of the E3 ubiquitin ligase Parkin from the cytosol 
to the damaged mitochondria.44 PINK1-mediated phosphorylation 
of Parkin induces a conformational change in the active form which 
ubiquitinates mitochondrial surface proteins such as the voltage-
dependent anion channel-1 (VDAC1) and Mitofusin 1, 2 (MFN1, 2), 
leading to mitochondrial autophagic removal.45,46 Another E3 ubiq-
uitin ligase, TNF-receptor-associated factor 2 (TRAF2), has also been 
shown to promote the removal of ubiquitin-tagged and damaged mi-
tochondria during IR injury, but in a Parkin-independent manner.47 
Two further Parkin-independent mechanisms of mitophagy involve 
mitochondrial outer membrane proteins: the mitochondrial pro-
apoptotic BH3 domain-only protein BNIP3 and FUNDC1.48 BNIP3 
is up-regulated in the myocardium during hypoxia49 and promotes 
mitophagy that does not require ubiquitination. Under hypoxic con-
ditions, FUNDC1 is dephosphorylated by phosphatases (eg PGAM5) 
at Serine 13, which induces protein interaction with microtubule-
associated proteins 1A/1B light chain 3 (LC3), thereby enhancing 
mitophagy.50,51
Mitophagy can be considered a beneficial cellular process that 
enhances cell viability following stressful stimuli by eliminating dys-
functional mitochondria. Mitophagy is therefore essential for cardio-
myocyte survival.52 Accumulated evidence suggests that IR causes 
an imbalance in the mitophagy process, and one could easily imagine 
6  |     DAVIDSON et Al.
how this would allow dysfunctional mitochondria to accumulate in 
the cell, causing further cytotoxic damage and potentially leading to 
cell death. However, it remains controversial whether it is excessive 
mitophagy or large-scale accumulation of autophagosomes that is 
the main mechanism underlying ‘autophagic cell death’.40,53,54 The 
emerging consensus is that cellular insults induce changes consistent 
with autophagosome formation and the initiation of autophagy in 
cardiac cells, and that these processes can lead to cell death.
The results of early studies of the role of autophagy in IR-
induced cardiomyocyte death were somewhat contradictory, indi-
cating that autophagy could be cyto-protective, but could also direct 
cells towards apoptosis.55 These observations are in contrast with 
the notion that autophagy may trigger cell death in a caspase-inde-
pendent way as assessed in vitro56 and in vivo,57 where it has been 
shown that impairing the expression of ATG genes leads to reduc-
tion of cell death. However, rigorous kinetic analyses are required to 
establish whether autophagic cell death is independent from apop-
totic or necrotic processes and whether it represents a step through 
which these processes culminate with cell disruption.53 Evidence 
from Sadoshima's group suggested that autophagy is beneficial 
during ischaemia but harmful during reperfusion.58 However, more 
recently, the balance of evidence favours a beneficial role for auto-
phagy in the heart under most conditions.59
5  | NECROPTOSIS
Necroptosis, a regulated mode of cell death with a necrotic appear-
ance, has been identified in various cardiac pathologies, including 
myocardial IR (reviewed in60,61). The precise cytotoxic mechanisms 
of necroptosis are not fully understood; however, the activation of 
RIP1 and RIP3 (receptor-interacting serine/threonine-protein ki-
nase 1 and 3) is essential for necroptotic cell membrane rupture-
inducing events that occur as a consequence of the relocalization 
to the plasma membrane of phosphorylated mixed-lineage kinase 
domain-like pseudokinase (MLKL) (Figure 2).62 Accordingly, the ma-
jority of studies of both acute63-67 and chronic myocardial IR injury 
progressing into heart failure68-70 indicate that membrane-asso-
ciated RIP1-RIP3-MLKL axis is a key player in necroptotic damage 
leading to worsening of heart function and adverse cardiac remodel-
ling. However, only a very limited number of experiments have in-
vestigated the importance of mitochondria in this process. By using 
a pharmacological inhibitor of RIP1, necrostatin-1 (Nec-1), which re-
duced infarct size in wild-type but not in CypD−/− mice, it has been 
suggested that cyclophilin D, an important regulatory component 
of the MPTP, might be involved in necroptosis signalling66 due to 
promotion of MPTP opening.67 RIP3-mediated activation of CaMKII 
(Ca2+-calmodulin-dependent protein kinase), serving as an upstream 
regulator of the MPTP, is likely to trigger this critical event in IR-
induced necro(pto)sis.71
Necroptosis has been seen to occur in both H9c2 cardiomyo-
blasts subjected to hypoxia/reoxygenation (HR) and in vivo rat hearts 
subject to IR, as evidenced by increased levels of RIP1, RIP3 and 
MLKL.72 An increase was also seen in the mitochondrial membrane 
protein PGAM5 (phosphoglycerate mutase family member 5), an 
atypical Ser/Thr phosphatase that dephosphorylates and activates 
the mitochondrial fission protein DRP1.72 Furthermore, PGAM5 
knockdown suppressed the generation of ROS and preserved ΔΨm, 
implicating mitochondria in the process of necroptosis.72 In a similar 
model of H9c2 subjected to HR, siRNA targeting RIP3 was shown to 
prevent mitochondrial fragmentation and necroptosis, by preventing 
activation of DRP1, again suggesting a link between necroptosis and 
mitochondria.73
Subcellular analyses have further revealed that RIP3 co-local-
izes with mitochondria69 or translocates to mitochondria during HR 
and interacts with DRP1, but not with RIP1 and MLKL.73 This pro-
vides evidence for necroptosis execution being independent of the 
canonical pathways these proteins are involved in.71 These findings 
suggest that RIP3-PGAM5-DRP1 cause mitochondrial dysfunction 
that promotes necroptosis. However, in contrast, Lu et al found that 
PGAM5 ablation was deleterious because it increased infarct size 
and exacerbated necroptosis.74 Promotion of mitophagy, which can 
prevent necroptosis by clearing ROS-producing unhealthy mito-
chondria,75 can underlie such a protective regulatory function of this 
protein phosphatase in necroptosis-associated conditions.
From the above discussion, it is evident that the extent of mi-
tochondrial participation in necroptosis in cardiomyocytes or other 
cell types is not clear. It has been suggested that the contribution 
of mitochondria to necroptosis may be secondary or context-de-
pendent.76 For instance, MLKL, the ultimate effector of necropto-
sis, is unlikely to directly assemble at mitochondrial membranes, as 
shown for the much higher efficiency of the MLKL N-terminal do-
main to permeabilize liposomes with a composition resembling the 
plasma membrane, in comparison with cardiolipin-rich liposomes.77 
Nonetheless, at early stages of SMAC-mimetic induced necroptosis 
in various cancer cell types, a disruption of mitochondrial membrane 
potential is observed that presumably depends on BAK-BAX activ-
ity.78 In accordance with this, the pro-apoptotic protein PUMA could 
act as an amplifier of necroptosis by exposing mitochondrial DNA 
to the cytosolic sensors, which further stimulates the necrosome 
formation.79 Moreover, at the inner mitochondrial membrane, MPTP 
response could be an important mediator of this kind of cell death, 
as either cyclosporine A treatment or cyclophilin D deficiency confer 
resistance to necroptosis prompted by TNFα exposure of endothelial 
cells.80 In summary, therefore, while specific mitochondrial mecha-
nisms in the membrane canonical pathway of necroptosis cannot be 
ruled out, the details remain to be elucidated.
6  | PYROPTOSIS
Pyroptosis, meaning ‘fire’ and ‘falling’, is a pro-inflammatory cell-
death program occurring after cytosolic receptor-mediated rec-
ognition of pathogen-associated molecular patterns (PAMPs), or 
host-derived, danger signals such as damage-associated molecu-
lar patterns (DAMPs). Some well-characterized DAMPs include 
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glucose-regulated proteins (GRPs), high-mobility group box 1 
(HMGB-1), IL-1β, S100 family proteins and some heat shock proteins 
(HSPs). Interaction of these proteins with cellular pattern recognition 
receptors can lead to the assembly of the intracellular NLRP3 inflam-
masome complex. The assembled NLRP3 inflammasome elicits auto-
proteolytic cleavage and activation of caspase-1, which mediates the 
cleavage/maturation of the pro-inflammatory cytokines, pro-IL-18 
and pro-IL-1β, and cleaves/activates gasdermin-D (GSDMD), releas-
ing its N-terminal fragment.81 Activated GSDMD-N, as well as ac-
tive caspase-1, may induce the formation of membrane pores thus 
inducing cell lysis, called pyroptotic cell death.82-84 The subsequent 
immune response triggered by DAMPs can lead to various forms of 
cell death, including apoptosis, pyroptosis, necrosis and necroptosis. 
Of note, bidirectional crosstalk between pyroptotic and apoptotic 
cell death mechanisms has been described: caspase-1 can cleave and 
activate caspase-3 and caspase-7 to start apoptosis, which in turn 
can cleave and inactivate GSDMD to limit pyroptosis.85 Likewise, a 
crosstalk between pyroptosis and necroptosis being associated with 
RIP3 and MLKL activation has also been suggested.86
The DAMPs released after cell death can induce further injury, 
thus causing a vicious cycle that expands the region of ischaemic 
damage. Evidence for a role of inflammasome/pyroptosis in acute 
myocardial IR injury comes from several studies.87 In 2001, pre-
ceding the notion of the inflammasome, it was reported that the 
secretion of IL-1β and IL-18 was increased in an IR model of iso-
lated human atrial myocardium.88 In 2003, targeted deletion of 
caspase-1 was shown to reduce early mortality and left ventricular 
dilation following cardiac infarction in mice, thus supporting a link 
between inflammasome activation, apoptosis and cardiovascular 
diseases.89 In 2011, Kawaguchi et al90 reported an essential role 
for cardiac fibroblasts inflammasome activation in myocardial IR 
injury. Simultaneously, Mezzaroma et al,91 using a gene silencing 
NLRP3 model, suggested that NLRP3 overexpression occurs not 
only in cardiac fibroblasts, but also in infiltrating cells and, impor-
tantly, in cardiomyocytes of the border zone of the infarct area. In 
2013, Sandanger et al reported a reduced infarct size in Nlrp3−/− 
mice in an ex vivo Langendorff perfused heart model of IR.92 Also 
using isolated hearts, it was confirmed that pre-treatment with the 
NLRP3 inhibitor, INF4E, reduced infarct size and improved ven-
tricular developed pressure after IR.93 These findings were con-
firmed by Luo et al in a type 2 diabetes rat model.94
The mechanisms of myocardial IR damage by DAMPs may in-
volve binding to receptor for AGE (advanced glycation end prod-
ucts, RAGE) or to TLR4 (toll-like receptor 4), thus activating NFκB 
and exacerbating myocardial damage. Indeed, among pro-inflam-
matory genes, NFκB promotes the transcription of components of 
the NLRP3 inflammasome in cardiac cells.95 Therefore, the NLRP3 
inflammasome may be considered a sensor that links myocardial 
damage to inflammation, thereby contributing to the progression of 
the wavefront of IR injury.96,97 After activation, the NLRP3 inflam-
masome promotes cardiomyocyte death and infarct size progression 
in the first hours of reperfusion likely through pyroptosis and then 
through production of IL-1β and inflammation.91,96
Despite the fact that IR-damaged myocardium releases a com-
bination of priming and triggering factors of the NLRP3 inflam-
masome, it has been proposed that the NLRP3 inflammasome in the 
heart is not sufficient to respond to a trigger signal in the absence 
of a priming.98 Actually, after IR, the size of the infarct is found to 
increase more in the presence of an active NLRP3,93,96,99 especially 
if metabolic syndrome has primed the inflammasome.99
Although little is known about the role of mitochondria in 
pyroptosis occurring in the myocardium specifically, there is ev-
idence for mitochondrial involvement in other cell types. In fact, 
mitochondrial dysfunction, leading to oxidative stress and mito-
chondrial DNA (mtDNA) release, is emerging as a key mechanism 
in triggering NLRP3 assembly and activation in several conditions 
and indeed has been proposed as the universal trigger for NLRP3 
activation.100,101 Mitochondrial ROS induce NLRP3-dependent 
lysosomal damage and further inflammasome activation.95,102 
ROS favour the mitochondrial localization of NLRP3 and ASC for 
further NLRP3 activation. VDAC1-induced ROS formation and 
BAX/BAK activation can also trigger NLRP3 activation. Calcium 
overload and calcium entry into mitochondria may favour MPTP 
opening thus generating ROS, which promote the deubiquitylation 
of NLRP3 and inflammasome activation, thus facilitating mtDNA 
release to further activate NLRP3.103 TLR4-IRF1 mediates tran-
scriptional up-regulation of UMP-CMPK2 (uridine/cytidine mo-
nophosphate kinase-2), which favours mtDNA synthesis and the 
formation of oxidized short strands of mtDNA that exit the mi-
tochondria.104 Also, exposed mitochondrial cardiolipin can tether 
NLRP3 to the mitochondria for activation in a ROS-dependent and 
ROS-independent fashion.105 Released cardiolipin in combination 
with ineffective mitophagy lead to NLRP3-mediated activation of 
caspase-1 and subsequent production of IL-1.105 Loss of BCL-XL 
and MCL-1 activity can activate BAX/BAK, which may favour 
NLRP3 activation, via downstream effectors (activated caspase-3 
and caspase-7), in a K+ efflux-dependent way. Furthermore, the 
serine threonine kinase NIMA-related kinase 7 (NEK7) is a pro-
moter of NLRP3 inflammasome assembly downstream of ROS and 
K+ efflux.106,107 In fact, the catalytic domain of NEK7 interacts 
with the NACHT/LRR domain to favour NLRP3 inflammasome 
activation.106,107 Intriguingly, this interaction may be disrupted by 
cytochrome c, an intrinsic/mitochondrial regulator of apoptosis, 
to limit pyroptotic cell death, in a sort of yin yang, bidirectional 
process between apoptosis and pyroptosis.85,107 Finally, it has also 
been proposed that mitophagy may dampen NLRP3 activation by 
removing injured mitochondria. Actually, NLRP3 activity and met-
abolic disease progression have been associated with low levels of 
mitochondrial mitofusin proteins and elevated levels of DRP1, es-
pecially in hyperglycaemic conditions.108,109 Yet, deletion of DRP1 
may lead to an increase in NLRP3-dependent caspase-1 activation 
and IL-1 secretion.110
Recent evidence has shown that autophagy is necessary to re-
duce myocardial damage after acute myocardial infarction, thus con-
firming that the autophagic process can limit the activation of the 
NLRP3 inflammasome by removing damaged mitochondria and that 
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impaired mitophagy may contribute to adverse cardiac remodelling 
in myocardial infarction.111,112
Arguing against an important role for NLRP3 inflammasome in 
cardiac injury is a work of Sandanger et al who reported that NLRP3 
inflammasome activation is cardioprotective during myocardial 
IR.113 Moreover, Hermansson et al found that NLRP3 levels were 
low in human ischaemic myocardial tissue compared with non-isch-
aemic control cardiac tissue.114 However, gene analysis showed mu-
tations in NLRP3 in human cardiac tissues from ischaemic patients, 
but not in those from non-ischaemic controls; the authors suggested 
that genetic defects in the inflammasome and related proteins may 
represent a background for promoting ischaemic cardiac disease. 
Yet, Zuurbier et al,115 testing the hypothesis that NLRP3 inflam-
masome, plays a role either in preconditioning (IPC) or in acute IR 
injury, observed that NLRP3 deletion did not affect cell death, but 
exacerbated IR-induced mechanical dysfunction. Moreover, NLRP3 
deletion abrogated the protective effects of IPC against IR damage. 
The authors proposed that the observed effects are due to an al-
tered IL-6/STAT3 dependent mechanism. Therefore, it is possible 
that some concomitant modifications of protective pathways may 
explain discordant results.116
7  | OTHER T YPES OF CELL DE ATH
Although the involvement of mitochondria in extrinsic and intrinsic 
apoptotic pathways is undeniable, and their role in necroptosis and 
pyroptosis is being elucidated, the degree to which mitochondria are 
involved in other, more newly recognized, forms of cell death has just 
begun to be disentangled. In this respect, ‘parthanatos’ entails cell 
death characterized by excessive activation of poly(ADP-ribose) pol-
ymerase-1 (PARP-1).117 PARP-1 transfers ADP-ribose to apoptosis-
inducing factor (AIF), which in turn translocates from mitochondria 
to the nucleus where it triggers large-scale DNA fragmentation and 
thus precipitates cell death.118,119 Hence, mitochondria are central 
to PARP-1-mediated cell death. Genetic disruption of this pathway 
protects mice against IR injury.120
‘Ferroptosis’ is a form of programmed cell death dependent on 
iron. Ferroptosis seems to converge on the BCL2-family protein 
member BID, promoting its translocation to the mitochondria where 
it causes profound mitochondrial fragmentation and dysfunction.121 
This suggests a major role for mitochondria during ferroptotic death. 
However, integrity of the anaplerotic mitochondrial glutaminolysis 
and the tricarboxylic acid cycle is indispensable for ferroptosis pro-
duced by erastin or cysteine starvation but not by glutathione per-
oxidase 4 deficiency.122 Besides, coenzyme Q, an essential electron 
carrier of the mitochondrial electron transport chain, ought to be 
able to suppress ferroptosis caused by glutathione peroxidase 4 deg-
radation by an as-yet-unknown mechanism, as the hydrophilic coen-
zyme Q analogue, idebenone, counteracts FIN56-induced death.123 
Furthermore, the outer membrane protein CDGSH iron sulphur 
domain 1 (CISD1) negatively regulates mitochondrial iron accumula-
tion, lipid peroxidation and erastin-induced ferroptosis.124
8  | TR ANSL ATIONAL PERSPEC TIVES
Although chemical inhibitors of specific cell death pathways are very 
effective in limiting infarct size after IR in the experimental setting, 
few studies have investigated these drugs in patients experiencing 
cardiac IR.3,6,16 The paucity of studies is partly because available 
cell death inhibitors may not be suitable for use in patients, due to 
insufficient specificity or incompletely determined pharmacokinet-
ics or pharmacodynamics. One exception is the CIRCUS trial which 
investigated whether CsA would prevent MPTP and mitochondrial-
mediated necrosis in STEMI patients; however, this unfortunately 
failed to provide evidence of benefit.125 There are many potential 
reasons for this, including the high prevalence of co-morbidities 
and the pharmacological background of patients, which may modify 
cell death pathways. This is discussed further in the accompanying 
review in this series, ‘Translational issues and mitoprotection’. One 
further explanation may be that cardiomyocytes that escape early 
MPTP-mediated death can go on to die via other pathways.126 If so, 
this may mean that such a single-target approach will always be des-
tined to fail, and an approach targeting multiple cell death and/or cell 
survival pathways may be necessary.4
9  | CONCLUSIONS
An important limitation in all investigations of cell death pathways 
is the methodology used to evaluate cell death in cardiomyocytes 
(Table 1). TUNEL staining can be misleading as it alone does not 
distinguish between cells undergoing apoptosis, necrosis or DNA 
repair.62 Caspase activity can be measured but is also not specific 
to apoptosis as caspases can be involved in other pathways of cell 
death. Cell-based assays for more recently described forms of cell 
death such as pyroptosis and necroptosis have not yet been devel-
oped and many used assays are rather nonspecific being limited to 
the detection of cell damage due to membrane rupture and impair-
ment of cell metabolic activity. Distinguishing between different 
forms of cell death is further complicated by the potential overlap 
between them, and sharing of common signalling components. In 
this regard, recently published guidelines offer useful advice to the 
use of different assays of cell death.62 However, complicating this 
analysis is the fact that different types of cell can exhibit different 
characteristics during cell death, and cardiomyocytes may exhibit 
some particular differences to other cell types. Using observations 
taken from immune cells to interpret the response of cardiomyo-
cytes to injury may not always lead to the correct interpretation and 
must be performed with care.
In summary, mitochondria seem to be a convergent point be-
tween various regulated cell death processes. In some cases, such 
as MPTP-mediated necrosis, apoptosis and parthanatos, their par-
ticipation is clear, whereas in other cases, such as necroptosis, the 
extent of their involvement might be context-dependent. In either 
case, increasing evidence points to a crosstalk between the diverse 
pathways of death, with mitochondria likely to be a central node of 
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all such pathways. They are therefore a key target for maintaining 
the health of cardiomyocytes during IR and thereby protecting the 
heart from injury.
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